Afuco™ Anti-Human RXFP1 ADCC Therapeutic Antibody, ADCC Enhanced
Anti-RXFP1 ADCC Enhanced Antibody is an ADCC enhanced antibody produced by our Afuco™ platform. The anti-LGR7 antibodies have antibody-dependent cell-mediated cytotoxicity (ADCC) activity and complement-dependent cytotoxicity (CDC) activity against LGR7-expressing cells. The anti-LGR7 antibodies are useful for diagnosis, prevention, and treatment of primary and metastatic ovarian clear cell adenocarcinoma.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-522CL |
| Pricing | Inquiry |
| Host | Mouse |
| Target | RXFP1 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store it under sterile conditions at -20°C upon receiving. Recommend to pack the protein into smaller quantities for optimal storage. |